Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
309.2 INR | -0.51% | -3.19% | +23.87% |
May. 24 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
May. 24 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 71% by 2026.
- The company's profit outlook over the next few years is a strong asset.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.84 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.51 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.87% | 4.42B | A- | ||
+11.91% | 118B | B+ | ||
+11.60% | 106B | B+ | ||
-4.68% | 24.28B | B+ | ||
-0.82% | 21.96B | B | ||
-10.12% | 18.16B | A- | ||
-42.12% | 16.37B | A- | ||
-17.47% | 15.56B | B | ||
+2.77% | 13.63B | C+ | ||
+34.58% | 12.27B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOCON Stock
- Ratings Biocon Limited